Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibacterial antisense.

Bruce L Geller1

  • 1AVI BioPharma and Oregon State University, Department of Microbiology, Corvallis, Oregon 97331, USA. gellerb@orst.edu

Current Opinion in Molecular Therapeutics
|April 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Retain Activity against Multidrug-Resistant Pseudomonas aeruginosa <i>In Vitro</i> and <i>In Vivo</i>.

mBio·2021
Same author

AcrAB-TolC Inhibition by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Antibiotic Activity <i>in Vitro</i> and <i>in Vivo</i>.

ACS infectious diseases·2019
Same author

Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae.

The Journal of antimicrobial chemotherapy·2018
Same author

Antisense Inhibitors Retain Activity in Pulmonary Models of Burkholderia Infection.

ACS infectious diseases·2018
Same author

MCR-1 Inhibition with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Sensitivity to Polymyxin in <i>Escherichia coli</i>.

mBio·2017
Same author

Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers.

Antimicrobial agents and chemotherapy·2017
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Antisense antibiotics offer a revolutionary approach by targeting specific genes to inhibit bacterial growth. Phosphorodiamidate morpholino oligomers (PMOs) show promise against various bacteria, with early animal studies demonstrating significant reduction in infections.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Drug Discovery

Background:

  • Traditional antibiotics target proteins, but resistance is a growing concern.
  • Antisense oligomers offer a novel strategy by targeting specific genetic sequences (rRNA or mRNA).
  • Peptide nucleic acids (PNAs) and phosphorodiamidate morpholino oligomers (PMOs) are promising antisense technologies.

Purpose of the Study:

  • To review the potential of antisense oligomers as a new class of antibiotics.
  • To highlight advances in antisense technology, including cellular uptake and bacterial susceptibility.
  • To discuss the therapeutic and non-therapeutic applications of antisense antibiotics.

Main Methods:

  • Sequence-specific targeting of bacterial genes, rRNA, or mRNA using antisense oligomers.

Related Experiment Videos

  • Evaluation of sequence-specific and dose-dependent inhibition of gene expression.
  • Assessment of cellular uptake improvements through oligomer shortening and peptide conjugation.
  • Testing susceptibility of various bacterial species, including Escherichia coli, Staphylococcus aureus, and Mycobacterium tuberculosis.
  • In vivo studies using mouse peritonitis models to assess therapeutic efficacy.

    • Main Results:

    • Antisense oligomers, particularly PMOs, inhibit gene expression in a sequence- and dose-dependent manner at low micromolar concentrations.
    • Improved cellular uptake enhances the effectiveness of antisense oligomers.
    • Susceptibility observed in key bacterial pathogens like E. coli, S. aureus, and M. tuberculosis.
    • PMOs demonstrated a significant reduction (approx. 10-fold) of E. coli in a mouse peritonitis model.
    • Antisense technology provides tools for target identification and antibiotic development.

    Conclusions:

    • Antisense antibiotics represent a revolutionary approach to combating bacterial infections.
    • PMOs show significant potential as gene-specific antibacterial agents.
    • Further preclinical studies are warranted to advance antisense antibiotic technology towards clinical application.
    • Non-therapeutic applications are crucial for advancing antibiotic research and development.